论文部分内容阅读
目的观察雾化吸入重组人干扰素α-2b辅治小儿手足口病的临床效果。方法将224例患有手足口病的患儿随机分为研究组和对照组各112例。对照组采用利巴韦林进行静脉注射,研究组在对照组基础上增加重组人干扰素α-2b雾化吸入治疗,对比2组临床疗效和症状体征持续时间。结果研究组患儿治疗总有效率为92.86%高于对照组的70.54%,差异均有统计学意义(P<0.05)。研究组发热、皮疹、口腔黏膜疹、易惊、精神不振、烦躁哭闹持续时间均短于对照组,差异均有统计学意义(P<0.05)。2组肌阵挛持续时间差异无统计学意义(P>0.05)。结论采用重组人干扰素α-2b雾化吸入辅治手足口病患儿临床疗效较优,能够明显缩短患儿临床症状及体征持续的时间,缩短患儿的治疗时间,减轻患儿痛苦,值得广泛推广应用。
Objective To observe the clinical effect of atomized inhalation of recombinant human interferon α-2b on children with hand-foot-mouth disease. Methods A total of 224 children with HFMD were randomly divided into study group and control group with 112 cases each. The control group was treated with ribavirin intravenously. The study group was treated with recombinant human interferon α-2b aerosol inhalation on the basis of the control group, and the clinical efficacy and duration of symptoms and signs were compared. Results The total effective rate of treatment group was 92.86% higher than 70.54% of control group, the difference was statistically significant (P <0.05). The study group fever, rash, oral mucosal rash, easy to panic, lack of energy, irritability crying duration were shorter than the control group, the difference was statistically significant (P <0.05). There was no significant difference in the duration of myoclonus between the two groups (P> 0.05). Conclusions The therapeutic effect of HFMD on children with hand-foot-mouth disease is superior, which can shorten the duration of clinical symptoms and signs, shorten the treatment time and reduce the pain of children Widely used.